Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to See if an iPhone Weight Management App Can Help Promote Weight Loss in Adolescents and Young Adults After a Stem Cell Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04453072
Recruitment Status : Recruiting
First Posted : July 1, 2020
Last Update Posted : March 29, 2021
Sponsor:
Collaborator:
eHealth International, INC.
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center

Brief Summary:
This early phase I trial studies how well a behavioral weight loss intervention consisting of a smartphone application and coaching works for the promotion of weight loss in adolescents and young adults after a stem cell transplant. This study may help researchers learn more about how adolescents and young adults can lose weight and develop healthy eating habits.

Condition or disease Intervention/treatment Phase
Obesity Malignant Neoplasm Other: Interview Other: Media Intervention Other: Questionnaire Administration Other: Scale Device Behavioral: Telephone-Based Intervention Other: Text Message Not Applicable

Detailed Description:

PRIMARY OBJECTIVE:

I. To evaluate the effectiveness of an addiction-based weight loss intervention, embodied as a smartphone application (app) with telephone coaching, on weight outcomes of overweight and obese post hematopoietic stem cell transplantation (HSCT) adolescents and young adults.

SECONDARY OBJECTIVES:

I. To evaluate the changes in metabolic parameters and physical activity levels, in addition to modifications in addictive eating behaviors, motivation, and self-regulatory behaviors.

II. To evaluate the feasibility, adherence, and satisfaction of this intervention.

OUTLINE:

Patients receive an iPhone with W8Loss2Go app, a body scale and a digital food scale to weigh themselves and food daily. Patients interact with coaches via text messages for 4 days weekly and receive weekly 15 minute phone calls for appointment reminders, emotional support, progress discussion, and follow up on items discussed in a prior visit or phone call. Patients also have telemedicine interviews with the coach lasting 60 minutes at 2 and 4 months to elicit both positive and negative impacts on weight management and to identify barriers such as emotional eating, displacement behaviors, poor coping skills to life stressors, and social challenges. Patients who opt to extend the intervention until month 12 attend an additional telemedicine meeting with the coach. Patients also complete questionnaires over approximately 1.5 hours.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Behavioral Weight Loss Intervention Utilizing Mobile Health Technology in Hematopoietic Stem Cell Transplant Patients (BWL001)
Actual Study Start Date : July 1, 2020
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Supportive Care (app, scales, coaching, questionnaire)
Patients receive an iPhone with W8Loss2Go app, a body scale and a digital food scale to weigh themselves and food daily. Patients interact with coaches via text messages for 4 days weekly and receive weekly 15 minute phone calls for appointment reminders, emotional support, progress discussion, and follow up on items discussed in a prior visit or phone call. Patients also have telemedicine interviews with the coach lasting 60 minutes at 2 and 4 months to elicit both positive and negative impacts on weight management and to identify barriers such as emotional eating, displacement behaviors, poor coping skills to life stressors, and social challenges. Patients who opt to extend the intervention until month 12 attend an additional telemedicine meeting with the coach. Patients also complete questionnaires over approximately 1.5 hours.
Other: Interview
Participate in interviews

Other: Media Intervention
Receive iPhone with W8Loss2Go app

Other: Questionnaire Administration
Complete questionnaires

Other: Scale Device
Receive body scale and food scale
Other Name: Scale

Behavioral: Telephone-Based Intervention
Receive telephone calls

Other: Text Message
Receive text message
Other Names:
  • Short Message Service (SMS) Text
  • SMS Text Message
  • Text




Primary Outcome Measures :
  1. Change in body mass index (BMI) status [ Time Frame: Baseline up to 12 months ]
    The main outcomes measures will be height (meters), weight (kg), and BMI (kg/m^2). Height will be measured to assess consistency in height measurements. Weight will be measured to assess trends in weight over the time span of the intervention. BMI will be measured as a product of weight and height to obtain an appropriate metric that accounts for these measures, and is the standard measure to assess weight progression in weight intervention studies.


Secondary Outcome Measures :
  1. Adherence [ Time Frame: Up to 12 months ]
    Compliance with app intervention will be measured by daily interaction with the application and the coach. A point system has been designed in the application to measure compliance with the app intervention, measured by +/- weight measured daily, logging of problem foods, logging of snacking panel, and logging of meals. The coach interacts with the participants through text daily, and through phone calls weekly.

  2. Fasting lab test analysis: HbA1c [ Time Frame: At four months up to 12 months ]
    HbA1c: Glycated hemoglobin (A1C) test result reflects your average blood sugar level for the past two to three months. Specifically, the A1C test measures what percentage of your hemoglobin is coated with sugar. The healthy range is between 4% and 5.6%

  3. Fasting lab test analysis: Total cholesterol [ Time Frame: At four months up to 12 months ]
    Total cholesterol: This measures the overall amount of cholesterol in your blood. The healthy range is < 170 mg/dL

  4. Fasting lab test analysis: Low density lipoprotein [ Time Frame: At four months up to 12 months ]
    LDL: low density lipoprotein (LDL) is the bad cholesterol in your blood. The healthy range is <100 mg/dL

  5. Fasting lab test analysis: High density lipoprotein [ Time Frame: At four months up to 12 months ]
    HDL: high density lipoprotein (HDL) is the good cholesterol in your blood. The healthy range is > 45 mg/dL

  6. Fasting lab test analysis: triglycerides [ Time Frame: At four months up to 12 months ]
    TG: triglycerides (TG) are a type of lipid in your blood. The healthy range is < 150 mg/dL

  7. Fasting lab test analysis: aspartate/alanine aminotransferase [ Time Frame: At four months up to 12 months ]
    AST/ALT: aspartate/alanine aminotransferase (AST/ALT) are liver enzymes to measure liver health. The healthy range or AST is 10-34 IU/L and the healthy range for ALT is 8-37 IU/L.

  8. Fasting lab test analysis: glucose [ Time Frame: At four months up to 12 months ]
    Glucose: This measures the amount of sugar in your blood. We measure this after fasting for 8 hours. The healthy range is 70-99 mg/dL

  9. Yale Food Addiction Scale [ Time Frame: Up to 12 months ]
    visual analog scale (1: never to 5:always). Higher scores may suggest more addictive like eating

  10. Center for epidemiologic studies depression scale [ Time Frame: Up to 12 months ]
    4 categorical options (never/rarely, sometimes, moderately, all of the time). A higher score suggests utility for screening for depression

  11. Perceived stress scale [ Time Frame: Up to 12 months ]
    Likert Scale (0: never to 4:very often). Higher scores suggests higher stress

  12. Satisfaction with program [ Time Frame: Up to 12 months ]
    Measured by "Satisfaction Survey". This Likert Scale will be completed by the participant and their parent at the end of the study. This scale uses a Likert Scale where 1 = completely disagree to 7 = completely agree. Higher scores suggest greater satisfaction with the intervention.

  13. Demographic questionnaire [ Time Frame: Up to 12 months ]
    10 questions with varying options to inquire about common demographic questions (gender, age, primary language, etc). Questions are descriptive in nature and no score is assigned.

  14. Food craving questionnaire [ Time Frame: Up to 12 months ]
    Likert scale (1: never to 5: always). A higher score suggests higher degrees of food cravings

  15. Binge eating disorder screen [ Time Frame: Up to 12 months ]
    4 categorical options (never/rarely, sometimes, often, always). A higher score suggests utility for screening for binge eating disorder

  16. Physical activity questionnaire [ Time Frame: Up to 12 months ]
    participants identify number of times (0 to more than 7) that they conducted a particular physical activity in the past 7 days. This includes skipping, rowing, etc.

  17. S weight [ Time Frame: Up to 12 months ]
    Likert scale (1: strongly disagree to 5: strongly agree). Higher scores indicates more motivation for change in weight

  18. Height encounters questionnaire [ Time Frame: Up to 12 months ]
    six questions about the participants health care utilization in the past month. Questions are descriptive in nature and no score is assigned.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   13 Years to 30 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients with a history of HSCT of any type, at least 100 days post-transplant at initial consultation of the study, will be eligible for the study
  • Patients must classify as obese, represented as body mass index (BMI) >= 85th percentile for age and gender
  • Patients must also be able to read English since the app intervention is only available in English form
  • No patients will be excluded for any specific underlying medical condition, but decisions will be made on a case by case basis if a patient's functioning is deemed to significantly interfere with intervention participation
  • PARENT:
  • His/her child meets all inclusion criteria
  • >= 18 years of age
  • Can speak English

Exclusion Criteria:

  • Patients who are < 100 days post-transplant at initial consultation will not be eligible for the study, but may become eligible if they are > 100 days post-transplant at their next consultation that falls within the enrollment window
  • Patients whose BMI does not fall under the obese category will be excluded

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04453072


Locations
Layout table for location information
United States, California
UCLA / Jonsson Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90095
Contact: Theodore B. Moore    310-794-8929    tbmoore@mednet.ucla.edu   
Principal Investigator: Theodore B. Moore         
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
eHealth International, INC.
Investigators
Layout table for investigator information
Principal Investigator: Theodore B Moore UCLA / Jonsson Comprehensive Cancer Center
Layout table for additonal information
Responsible Party: Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT04453072    
Other Study ID Numbers: 19-001992
NCI-2020-02687 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
19-001992 ( Other Identifier: UCLA / Jonsson Comprehensive Cancer Center )
First Posted: July 1, 2020    Key Record Dates
Last Update Posted: March 29, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Weight Loss
Body Weight Changes
Body Weight